Sanford-Burnham, Intrexon Strike iPSC Collaboration | GenomeWeb

NEW YORK (GenomeWeb News) – Sanford-Burnham Medical Research Institute and Intrexon have struck a collaboration focused on developing new induced pluripotent stem cell technologies for research purposes, the institute said today.

Under the plan, Sanford-Burnham researchers will use Intrexon's RheoSwitch Therapeutic System (RTS) and its Laser-Enabled Analysis and Processing (LEAP) instrument for cellular selection and gene regulation purposes. Intrexon may obtain commercial and intellectual property rights to technologies that result from the partnership, Sanford-Burnham said.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The Wall Street Journal reports that National Institutes of Health Director Francis Collins' response to contamination concerns at the agency might have delayed care.

The final revision of the Common Rule doesn't include the proposed change requiring consent for leftover biospecimens.

The first Reproducibility Project: Cancer Biology papers show mixed results.

In Nature this week: mobile phone-based targeted DNA sequencing, and more.